Supply Chain Intelligence

Corbus Pharmaceuticals Holdings, Inc. Supply Chain

CRBP supply chain intelligence for Corbus Pharmaceuticals Holdings, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

CRBP ·Last updated 2026-09-13 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

6Suppliers
18Customers
3Debt Items
20Related Chains

Source-Backed Evidence Depth

Corbus Pharmaceuticals Holdings, Inc. (CRBP) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

28Total relationships
2Distinct source URLs
9High confidence
0.758Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Corbus Pharmaceuticals Holdings, Inc. Suppliers

TickerNameConfidenceEvidence
CSPC CSPC 90% We are a party to a license agreement with CSPC pursuant to which we licensed the exclusive rights in the U.S., Canada, the European Union (including the European Free Trade Area), the U.K., and Aust…
CSPC-MEGALITH-BIOPHARMACEUTICAL-CO-LTD CSPC-MEGALITH-BIOPHARMACEUTICAL-CO-LTD 90% The Company paid CSPC an upfront payment of $ 7.5 million
JENRIN-DISCOVERY-LLC JENRIN-DISCOVERY-LLC 90% On September 20, 2018, we entered into an exclusive license agreement (the "Jenrin License Agreement") with Jenrin Discovery, LLC ("Jenrin"), which provides us with an exclusive worldwide license to …
THE-REGENTS THE-REGENTS 90% The Company paid The Regents a license issue fee of $ 1.5 million
JENRIN JENRIN 85% The Company is obligated to pay Jenrin up to $ 18.0 million in additional potential milestone payments
PLRX Pliant Therapeutics, Inc. 72% Reciprocal relationship from PLRX graph: duct candidates and jeopardize our ability to commercialize our product candidates and generate revenue. 32 In addition, there are risks associated with large…

Corbus Pharmaceuticals Holdings, Inc. Customers

TickerNameConfidenceEvidence
AZN AstraZeneca PLC 72% Reciprocal relationship from AZN graph: Reciprocal relationship from CRBP graph: designed to be an improved next-generation site-specific Nectin-4 targeting antibody drug conjugate. CRB-701 is a mono…
AZN AstraZeneca PLC 72% designed to be an improved next-generation site-specific Nectin-4 targeting antibody drug conjugate. CRB-701 is a monoclonal antibody attached to an MMAE cytotoxic payload using a proprietary linker …
BCYC Bicycle Therapeutics plc 72% Reciprocal relationship from BCYC graph: Reciprocal relationship from CRBP graph: Reciprocal relationship from BCYC graph: Reciprocal relationship from CRBP graph: designed to be an improved next-gen…
BCYC Bicycle Therapeutics plc 72% designed to be an improved next-generation site-specific Nectin-4 targeting antibody drug conjugate. CRB-701 is a monoclonal antibody attached to an MMAE cytotoxic payload using a proprietary linker …
GNMSF Genmab A/S 72% Reciprocal relationship from GNMSF graph: Reciprocal relationship from CRBP graph: Reciprocal relationship from GNMSF graph: Reciprocal relationship from CRBP graph: Reciprocal relationship from GNMS…
GNMSF Genmab A/S 72% designed to be an improved next-generation site-specific Nectin-4 targeting antibody drug conjugate. CRB-701 is a monoclonal antibody attached to an MMAE cytotoxic payload using a proprietary linker …
GPCR Structure Therapeutics Inc. 72% Reciprocal relationship from GPCR graph: Reciprocal relationship from CRBP graph: designed to be an improved next-generation site-specific Nectin-4 targeting antibody drug conjugate. CRB-701 is a mon…
GPCR Structure Therapeutics Inc. 72% designed to be an improved next-generation site-specific Nectin-4 targeting antibody drug conjugate. CRB-701 is a monoclonal antibody attached to an MMAE cytotoxic payload using a proprietary linker …
NVO Novo Nordisk A/S 72% Reciprocal relationship from NVO graph: Reciprocal relationship from CRBP graph: Reciprocal relationship from NVO graph: Reciprocal relationship from CRBP graph: Reciprocal relationship from NVO grap…
NVO Novo Nordisk A/S 72% designed to be an improved next-generation site-specific Nectin-4 targeting antibody drug conjugate. CRB-701 is a monoclonal antibody attached to an MMAE cytotoxic payload using a proprietary linker …
PLRX Pliant Therapeutics, Inc. 72% Reciprocal relationship from PLRX graph: duct candidates and jeopardize our ability to commercialize our product candidates and generate revenue. 32 In addition, there are risks associated with large…
VKTX Viking Therapeutics, Inc. 72% Reciprocal relationship from VKTX graph: Reciprocal relationship from CRBP graph: designed to be an improved next-generation site-specific Nectin-4 targeting antibody drug conjugate. CRB-701 is a mon…
VKTX Viking Therapeutics, Inc. 72% designed to be an improved next-generation site-specific Nectin-4 targeting antibody drug conjugate. CRB-701 is a monoclonal antibody attached to an MMAE cytotoxic payload using a proprietary linker …
CORBUS-PHARMACEUTICALS-INC CORBUS-PHARMACEUTICALS-INC 62% o execute trades in shares of our common stock. Our failure to maintain compliance with Nasdaq’s continued listing requirements could result in the delisting of our common stock. Our common stock is …
CORPORATE-INFORMATION-CORBUS-PHARMACEUTICALS-INC CORPORATE-INFORMATION-CORBUS-PHARMACEUTICALS-INC 62% ter coverage and reimbursement for certain healthcare items and services furnished to the elderly and disabled. Medicaid is an insurance program for certain categories of patients whose income and as…
JB-THERAPEUTICS-INC JB-THERAPEUTICS-INC 62% ter coverage and reimbursement for certain healthcare items and services furnished to the elderly and disabled. Medicaid is an insurance program for certain categories of patients whose income and as…
K2-HEALTHVENTURES-LLC K2-HEALTHVENTURES-LLC 62% study will follow 240 U.S. subjects randomized into 4 arms (placebo, 20 mg, 40 mg, and 60 mg) over a 12-week treatment period followed by a 4-week safety follow-up. Completion is expected in summer 2…
NATURE-OF-OPERATIONS-BUSINESS-CORBUS-PHARMACEUTI NATURE-OF-OPERATIONS-BUSINESS-CORBUS-PHARMACEUTI 62% accrued research and development expenses was also identified as a critical accounting estimate by management. F- 2 We identified the accruals for research and development expenses as a critical audi…

Corbus Pharmaceuticals Holdings, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
CRBP-DEBT-8833 Warrants outstanding: 2873 90% xbrl warrant detail from xbrl 2025-12-31.
CRBP-DEBT Debt stack $12.8M 90% Market cache reports total debt of $12.8M.
CRBP-DEBT-8834 Xbrl Convertible 90% xbrl convertible detail from xbrl 2014-12-31.

Corbus Pharmaceuticals Holdings, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Corbus Pharmaceuticals Holdings, Inc..

Corbus Pharmaceuticals Holdings, Inc. Ownership

HolderNameConfidenceEvidence
CRBP-OWNER-CORMORANT-ASSET-MANAGEMENT-LP Cormorant Asset Management, LP 90% 13F overlay lists Cormorant Asset Management, LP as top holder; 107 tracked holders.

Corbus Pharmaceuticals Holdings, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
BOLT Bolt Biotherapeutics, Inc. 100.00 2
GHRS GH Research PLC 100.00 2
BCAX Bicara Therapeutics Inc. 100.00 2
CPMV Mosaic ImmunoEngineering, Inc. 100.00 2
CTNM Contineum Therapeutics, Inc. 100.00 2
EVAX Evaxion A/S 100.00 2
SDGR Schrödinger, Inc. 100.00 2
ALNY Alnylam Pharmaceuticals, Inc. 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
GMAB Genmab A/S 100.00 2
DEO Diageo plc 100.00 2
CHRS Coherus Oncology, Inc. 100.00 2
CCCC C4 Therapeutics, Inc. 100.00 2
LGND Ligand Pharmaceuticals Incorporated 100.00 2
HTGC Hercules Capital, Inc. 100.00 2
CANF Can-Fite BioPharma Ltd. 100.00 2
DAWN Day One Biopharmaceuticals Inc 100.00 2
ALLO Allogene Therapeutics, Inc. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
GPCR Structure Therapeutics Inc. 100.00 1 ['customer']
Browse supply chain intel →

See the full supply chain map, all relationships, and real-time alerts for Corbus Pharmaceuticals Holdings, Inc..

Unlock full CRBP data — View plans →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map
🔐
CRBP
Unlock CRBP Supply Chain Data
Verified relationships include:
CSPCCSPCSupplier90%
CSPC-MEGALITH-BIOPHARMACEUTICAL-CO-LTDCSPC-MEGALITH-BIOPHARMACE…Supplier90%
AZNAstraZeneca PLCCustomer72%
AZNAstraZeneca PLCCustomer72%
+24 more relationships locked
Subscribe — View plans →
Already a subscriber? Sign in →